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Hematopoietic stem cells (HSCs) have been applied in clinic settings for treating hematologic diseases, 
including leukemic disorders, immune deficiencies, and hemoglobinopathies. Umbilical cord blood(UCB) is an 
important source of HSCs. However, the low frequency of HSCs per unit of UCB remains a big hurdle to their 
wider applications. Wnt/β-catenin pathway plays important roles in the self-renewal of HSCs in vivo, but the 
roles of Wnt/β-catenin signaling on ex vivo expansion of HSCs remains controversial. GSK3β is the major 
regulator of Wnt pathway. Here, we evaluate the effects of 6-bromoindirubin-3’-oxime (BIO), a GSK3β inhibitor, 
on ex vivo expansion characteristics and regenerative potential of (UCB)-derived CD34+ cells. 
 
First, the expansion of CD34+ cells at the presence of different concentrations of BIO was examined. Compared 
to the control, BIO treatment favored the expansion of CD34+ cells within the 4-day culture, while there was a 
trend toward repress the expansion of CD34+ cells on day 7. These results indicated that Wnt/β-catenin pathway 
is potentially related to the expansion of CD34+ cells. Subsequently, western bolt analysis showed that the 
amounts of β-catenin, phosphorylated GSK3β, and downstream effector Cyclin D1 were unchanged by BIO 
treatment at days 4 of culture. Notably, the β-catenin accumulated gradually with the prolongation of culture time 
peaking at day 7 with BIO treated. However, transcription factor TCF showed significant decrease at days 7 
compared to days 4 of culture. Remarkable increase in total CFU number was observed in BIO-treated cells 
relative to control, mainly because the frequency of CFU-GM (granulocyte, macrophage) was significantly 
higher. The expansion fold of total cells derived from BIO-cultured CD34+ cells favored the secondary 
expansion of total cells at day 4 and 14. 
 
In conclusion, Wnt/β-catenin signaling agonist BIO regulated the expansion of CD34+ cells and differential 
expression of key factors in Wnt signaling pathway in a β-catenin-dependent fashion during ex vivo culture. 
Furthermore, BIO-expanded CD34+ cells showed better multilineage commit potential and secondary expansion 
ability, which provides a valuable guidance for optimizing ex vivo culture. 
 
 
 
 
Figure 1 (A)The effect of BIO on expansion fold of CD34+ cells (*p<0.05，n=3). (B) Western blot analysis 
of for β-catenin, TCF, Cyclin D1 and phosphorylated GSK3β in CB CD34+ cells. (C, D) CFU and the 
secondary expansion ability analysis of expanded-CD34+ cells (*p<0.05，n = 3 experiments). 
 
